Search Results - "Daver, A"

Pooled Analysis of Prognostic Impact of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in 8377 Breast Cancer Patients by Look, Maxime P., van Putten, Wim L. J., Duffy, Michael J., Harbeck, Nadia, Christensen, Ib Jarle, Thomssen, Christoph, Kates, Ronald, Spyratos, Frédérique, Fernö, Mårten, Eppenberger-Castori, Serenella, Sweep, C. G. J. Fred, Ulm, Kurt, Peyrat, Jean-Philippe, Martin, Pierre-Marie, Magdelenat, Henri, Brünner, Nils, Duggan, Catherine, Lisboa, Björn W., Bendahl, Pär-Ola, Quillien, Véronique, Daver, Alain, Ricolleau, Gabriel, Meijer-van Gelder, Marion E., Manders, Peggy, Fiets, W. Edward, Blankenstein, Marinus A., Broët, Philippe, Romain, Sylvie, Daxenbichler, Günter, Windbichler, Gudrun, Cufer, Tanja, Borstnar, Simona, Kueng, Willy, Beex, Louk V. A. M., Klijn, Jan G. M., O'Higgins, Niall, Eppenberger, Urs, Jänicke, Fritz, Schmitt, Manfred, Foekens, John A.

“…Background: Urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) play essential roles in tumor invasion and metastasis. High levels of both uPA…”
Get full text

Thymidine Kinase as a Proliferative Marker: Clinical Relevance in 1,692 Primary Breast Cancer Patients by BROËT, P, ROMAIN, S, DAVER, A, RICOLLEAU, G, QUILLIEN, V, RALLET, A, ASSELAIN, B, MARTIN, P. M, SPYRATOS, F

“…To assess the prognostic value of thymidine kinase (TK), an enzyme involved in the DNA synthesis salvage pathway, relative to other prognostic factors in…”
Get full text

Long‐term follow‐up of salvage therapy using a combination of inotuzumab ozogamicin and mini–hyper‐CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome–negative acute lymphoblastic leukemia by Jabbour, Elias, Sasaki, Koji, Short, Nicholas J., Ravandi, Farhad, Huang, Xuelin, Khoury, Joseph D., Kanagal‐Shamanna, Rashmi, Jorgensen, Jeffrey, Khouri, Issa F., Kebriaei, Partow, Jain, Nitin, Alvarado, Yesid, Kadia, Tapan M., Paul, Shilpa, Garcia‐Manero, Guillermo, Dabaja, Bouthaina S., Burger, Jan A., DiNardo, Courtney D., Daver, Naval A., Montalban‐Bravo, Guillermo, Yilmaz, Musa, Ohanian, Maro, Ferrajoli, Alessandra, Jacob, Jovitta, Rostykus, Meagan, Garris, Rebecca, O’Brien, Susan, Kantarjian, Hagop M.

“…BACKGROUND The outcome of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) is poor. The combination of inotuzumab with low‐intensity…”
Get full text

Influence of Scanning Doses of Iodine- 131 on Subsequent First Ablative Treatment Outcome in Patients Operated on for Differentiated Thyroid Carcinoma by Muratet, Jean-Pierre, Daver, Alain, Minier, Jean-Francois, Larra, Francis

“…The therapeutic outcome after (131)I first ablative treatment in patients operated on for nonmedullary differentiated thyroid carcinoma was compared after both…”
Get full text

Summary report of the Standards, Options and Recommendations for the use of serum tumour markers in breast cancer: 2000 by Basuyau, J P, Blanc-Vincent, M P, Bidart, J M, Daver, A, Deneux, L, Eche, N, Gory-Delabaere, G, Pichon, M F, Riedinger, J M

Get full text

Prognostic value of uPA and p53 accumulation measured by quantitative biochemical assays in 1245 primary breast cancer patients: a multicentre study by BROËT, P, SPYRATOS, F, ROMAIN, S, QUILLIEN, V, DAVER, A, RICOLLEAU, G, RALLET, A, TOULAS, C, ASSELAIN, B

“…The purpose of this retrospective multicentre study was to assess the prognostic value of urokinase plasminogen activator (uPA) and p53 levels in a large…”
Get full text

Plasma sialic acid as a marker of the effect of the treatment on metastatic colorectal cancer by Painbeni, T., Gamelin, E., Cailleux, A., Le Bouil, A., Boisdron-Celle, M., Daver, A., Larra, F., Allain, P.

“…The concentration of total sialic acid (TSA) is increased in the plasma of patients with many types of cancer. The purpose of this study was to assess the…”
Get full text

Quantitative analysis of BRCA1, BRCA2 and Hmsh2 mRNA expression in colorectal lieberkühnien adenocarcinomas and matched normal mucosa : Relationship with cellular proliferation by LE CORRE, L, VISSAC-SABATIER, C, CHALABI, N, BIGNON, Y.-J, DAVER, A, CHASSEVENT, A, BERNARD-GALLON, D. J

“…The human DNA mismatch repair gene hMSH2 is involved in the development of sporadic and hereditary nonpolyposis colorectal cancer. An increased risk of…”
Get full text

Summary of the Standards, Options and Recommendations for the management of patients with nonmetastatic prostate cancer (2001) by Villers, A, Pommier, P, Bataillard, A, Fervers, B, Bachaud, J M, Berger, N, Bertrand, A F, Bouvier, R, Brune, D, Daver, A, Fontaine, E, Haillot, O, Lagrange, J L, Molinie, V, Muratet, J P, Pabot du Chatelard, P, Peneau, M, Prapotnich, D, Ravery, V, Richaud, P, Rossi, D, Soulie, M

Get full text

Yirminci asırda Çorum tarihinden notlar: Z.A. Daver Kolağasıoğlu by Kolağasıoğlu, Z. A. Daver

Get more information

Quantitative determination of c-erbB-2 in human breast tumours : Potential prognostic significance of low values by KOSCIELNY, S, TERRIER, P, DAVER, A, WAFFLART, J, GOUSSARD, J, RICOLLEAU, G, DELVINCOURT, C, DELARUE, J. C

“…The purpose of this prospective multicentric study was to quantify the c-erbB-2 protein and investigate its relationship with DNA amplification and with…”
Get full text

ras, p53 and HPV status in benign and malignant prostate tumors by Moyret-Lalle, C, Marçais, C, Jacquemier, J, Moles, J P, Daver, A, Soret, J Y, Jeanteur, P, Ozturk, M, Theillet, C

“…To study the role of ras, p53 genes and HPV virus (16 and 18) in the development of prostate cancer, we analyzed tissue sections from 27 patients affected with…”
Get more information

Values for the free to total prostate-specific antigen ratio as a function of age: necessity of reference range validation by Chautard, D, Daver, A, Mermod, B, Tichet, A, Bocquillon, V, Soret, J

“…To measure the levels of free prostate-specific antigen (PSA), total PSA, and free to total PSA ratio in a population of men with no known prostate pathology…”
Get more information

Loss of heterozygosity at the ATM locus in colorectal carcinoma by Uhrhammer, N, Bay, J, Pernin, D, Rio, P, Grancho, M, Kwiatkowski, F, Gosse-Brun, S, Daver, A, Bignon, Y

“…Patients homozygous for mutation of the ATM gene exhibit constitutional genetic instability and have a high risk of cancer. A-T heterozygotes also have an…”
Get more information

p185 overexpression in 220 samples of breast cancer undergoing primary surgery: comparison with c-erbB-2 gene amplification by Dalifard, I, Daver, A, Goussard, J, Lorimier, G, Gosse-Brun, S, Lortholary, A, Larra, F

“…In breast cancer, DNA amplification of the oncogene c-erbB-2, encoding for the p185 protein, is associated with a poor prognosis. A retrospective study on a…”
Get more information

Sensitivity and specificity of elastase by Charneau, J, Douay, O, Daver, A, Boyer, J

Get full text

Kinetics of Serum Tumor Marker Concentrations and Usefulness in Clinical Monitoring by Bidart, Jean-Michel, Thuillier, Francois, Augereau, Christine, Chalas, Jacqueline, Daver, Alain, Jacob, Nelly, Labrousse, Francoise, Voitot, Helene

“…Only a few markers have been instrumental in the diagnosis of cancer. In contrast, tumor markers play a critical role in the monitoring of patients. The…”
Get full text

Quel avenir pour les dosages des marqueurs tumoraux sériques ? by Basuyau, J.P, Daver, A, Floiras, J.L, Pecking, A, Pichon, M.F

“…Le texte de cette table ronde a été retranscrit durant la session « Avancées dans la Biologie des Cancers » pendant le 18 e colloque CORATA (Nantes, 26 octobre…”
Get full text

Immunostaining of colorectal cancer with monoclonal anti-CEA antibodies compared to serum and tumor CEA content by Pagé, M, Dalifard, I, Bertrand, G, Bocquillon, P G, Daver, A

“…Carcinoembryonic antigen was measured in serum and in extracts from 37 colorectal tumors and we found a poor correlation between circulating and tumor CEA…”
Get more information

The usefulness of prostate-specific antigen and prostatic acid phosphatase in clinical practice by Daver, A, Soret, J Y, Coblentz, Y, Allain, Y M, Cellier, P, Chauveau, P

“…A comparative study was performed on the usefulness of prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP) in control subjects (69), benign…”
Get more information